Business Standard

Over half of large-cap schemes lag Nifty100 amidst weak market breadth

17 of 37 schemes beat index's returns of -6.4%, but only 3 were positive

markets, stock market, shares, valuations, economy, gdp, growth, investment, FDI, FPI, index
Premium

The Nifty50 has rallied thanks to the outperformance of a select few names such as Dr Reddy’s Laboratories, Divi’s Laboratories, Cipla, Infosys, Reliance Industries, and Wipro

Ashley Coutinho Mumbai
A little over half of the 37 large-cap schemes have underperformed the Nifty100 index year-to-date.

Seventeen schemes beat the benchmark’s returns of -6.4 per cent given this year, of which only three schemes have provided positive returns, data from Value Research shows. JM Core 11 Fund has been the worst performer, with returns of -17.6 per cent. Only regular plans were considered. 

The Nifty50 has rallied thanks to the outperformance of a select few names such as Dr Reddy’s Laboratories, Divi’s Laboratories, Cipla, Infosys, Reliance Industries, and Wipro. In the Nifty100 universe, only 29 per cent of stocks have provided double-digit returns,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in